The company reported $26 million in total revenues for the quarter and said that testing services revenues more than doubled year over year.
The firm said that it placed about 50 sample-to-answer molecular systems under contract during Q1, and it had about 625 active sample-to-answer product customers.
Within diagnostics, molecular revenues were up 11 percent year over year to $167.8 million. The firm received two new CE marks for early infant diagnosis and testing dried blood spots.
For the quarter ended March 31, Twist reported $13.6 million in revenues, up from $6.2 million during the same period last year.
It placed 39 net new ePlex analyzers, expanding the global installed base to 393 placements and growing its installed base by 72 percent compared to the prior-year period.
The firm reported that test volumes for its Cologuard colorectal cancer screening test also rose 79 percent year over year.
The company increased its 2019 revenue forecast and shrunk its net loss significantly in its push to become cash flow breakeven by the end of the year.
The firm's clinical service revenues were up also 51 percent, and it also announced it has signed a contract with insurer Humana.
While total revenues were up less than 1 percent, the Diagnostics division grew revenues 5 percent. Discovery & Analytical Solutions dipped 2 percent.
The Life Sciences business grew 10 percent year over year, while the Diagnostics business inched up 1 percent.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.